Emmes, a global, full-service CRO, has acquired Orphan Reach, a company headquartered in the UK with offices in Ireland, Germany, India, Canada, and the U.S., dedicated to clinical research in rare diseases.   This is Emmes’ second acquisition in the past four months, following the acquisition of Neox s.r.o., an EU-based CRO, in December 2020. Neox and Orphan Reach expand Emmes’ global reach with their international footprints and add a larger and more diverse set of biopharmaceuti...